Literature DB >> 10398643

Economics notes: handling uncertainty in economic evaluation.

A Briggs1.   

Abstract

Mesh：

Year:  1999        PMID： 10398643      PMCID： PMC1116199          DOI： 10.1136/bmj.319.7202.120

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  4 in total

1.  The reliability of cost-utility estimates in cost-per-QALY league tables .

Authors:  S Petrou; M Malek; P G Davey
Journal:  Pharmacoeconomics       Date:  1993-05       Impact factor: 4.981

2.  Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane.

Authors:  A Briggs; P Fenn
Journal:  Health Econ       Date:  1998-12       Impact factor: 3.046

3.  In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care.

Authors:  B J O'Brien; M F Drummond; R J Labelle; A Willan
Journal:  Med Care       Date:  1994-02       Impact factor: 2.983

Review 4.  Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis.

Authors:  A Briggs; M Sculpher; M Buxton
Journal:  Health Econ       Date:  1994 Mar-Apr       Impact factor: 3.046
  4 in total
  20 in total

1.  Being economical with the truth: how to make your idea appear cost effective.

Authors:  S Goodacre; C McCabe
Journal:  Emerg Med J       Date:  2002-07       Impact factor: 2.740

2.  Cost-effectiveness analysis comparing two approaches for empirical antifungal therapy in hematological patients with persistent febrile neutropenia.

Authors:  Almudena Martín-Peña; M Victoria Gil-Navarro; Manuela Aguilar-Guisado; Ildefonso Espigado; Maite Ruiz Pérez de Pipaón; José Falantes; Jerónimo Pachón; José M Cisneros
Journal:  Antimicrob Agents Chemother       Date:  2013-07-15       Impact factor: 5.191

3.  The direct and indirect cost of diabetes in Italy: a prevalence probabilistic approach.

Authors:  A Marcellusi; R Viti; A Mecozzi; F S Mennini
Journal:  Eur J Health Econ       Date:  2014-11-27

4.  Cost-effectiveness analysis of n-3 polyunsaturated fatty acids (PUFA) after myocardial infarction: results from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-Prevenzione Trial.

Authors:  M G Franzosi; M Brunetti; R Marchioli; R M Marfisi; G Tognoni; F Valagussa
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

5.  A cost-effectiveness analysis of pneumococcal vaccination in street-involved, HIV-infected patients.

Authors:  C A Marra; D M Patrick; F Marra
Journal:  Can J Public Health       Date:  2000 Sep-Oct

6.  Value of information in the osteoarthritis setting: cost effectiveness of COX-2 selective inhibitors, traditional NSAIDs and proton pump inhibitors.

Authors:  Nicholas Latimer; Joanne Lord; Robert L Grant; Rachel O'Mahony; John Dickson; Philip G Conaghan
Journal:  Pharmacoeconomics       Date:  2011-03       Impact factor: 4.981

7.  Substantial potential for reductions in coronary heart disease mortality in the UK through changes in risk factor levels.

Authors:  J A Critchley; S Capewell
Journal:  J Epidemiol Community Health       Date:  2003-04       Impact factor: 3.710

8.  Potential population impact of the UK government strategy for reducing the burden of coronary heart disease in England: comparing primary and secondary prevention strategies.

Authors:  I Gemmell; R F Heller; K Payne; R Edwards; M Roland; P Durrington
Journal:  Qual Saf Health Care       Date:  2006-10

9.  Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis.

Authors:  Nicholas Latimer; Joanne Lord; Robert L Grant; Rachel O'Mahony; John Dickson; Philip G Conaghan
Journal:  BMJ       Date:  2009-07-14

10.  Return on investment of internet delivered exposure therapy for irritable bowel syndrome: a randomized controlled trial.

Authors:  Hugo Wallén; Perjohan Lindfors; Erik Andersson; Erik Hedman-Lagerlöf; Hugo Hesser; Nils Lindefors; Cecilia Svanborg; Brjánn Ljótsson
Journal:  BMC Gastroenterol       Date:  2021-07-13       Impact factor: 3.067
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.